Foreword: Why Ningxiang
On July 18, 2024, Micropeptide Group's factory in Ningxiang Economic Development Zone, Hunan, was officially put into production.
This matter was discussed within the group for 3 years. In 2019, when Guangdong Micropeptide had been doing medical device OEM for 5 years, Group CEO Lao Wang said at the annual meeting: In the future, we must build a factory in Central China. At that time, many people thought it was unnecessary—the production base in Guangdong was already sufficient, and there was surplus capacity.
By 2022, views changed. Two things touched us:
First thing: In Q3 2022, high-temperature power restrictions in South China caused the Guangdong factory to suspend production for 2 weeks. Customers urged orders to the extreme, and within 2 weeks we lost 3 long-term customers. It was not a capacity problem, but a risk problem of "capacity concentrated in a single region."
Second thing: In 2023, a major customer suddenly asked: Can you find an OEM factory in Central China to make medical device products for us? The reason was that their medical aesthetics channel customers were concentrated in Changsha, Wuhan, and Nanchang, and shipping from Guangdong had high logistics costs and slow emergency replenishment.
In addition, starting in 2023, the group's medical device OEM business has grown at an annual rate of over 60% (data source: group internal financial statistics), and the existing production capacity in Guangdong + Foshan + Zhaoqing began to be strained.
Building a Central China factory had to be done.
I. Why Choose Ningxiang
In Q1 2023, we spent 3 months traveling across Hunan, Hubei, and Jiangxi provinces, and finally chose Ningxiang Economic Development Zone in Hunan. There were 5 core reasons:
First, industrial chain support. Ningxiang Economic Development Zone is one of the largest pharmaceutical industrial parks in Hunan, gathering a number of pharmaceutical companies such as Truking Technology, Erkang Pharmaceutical, and Jiuzhitang. Resources for cosmetics/medical device raw materials, packaging materials, and testing and inspection are available, and supply chain efficiency is much higher than transferring goods from Guangdong.
Second, geographical location. Ningxiang is 40 minutes from Changsha Huanghua Airport, 50 minutes from Changsha South Station, 3.5 hours from Wuhan, 3 hours from Nanchang, and 6 hours from Guangzhou. It can cover both major customer groups in Central and South China.
Third, policy benefits. Hunan Province's "specialized, refined, distinctive and innovative" enterprise recognition, Changsha City's high-level talent introduction policy, and Ningxiang Economic Development Zone's three-year tax exemption and three-year half reduction—these can save 15%-20% of upfront investment.
Fourth, talent. Hunan University of Chinese Medicine, Hunan University, and Hunan Normal University are all in Changsha. More than 5,000 undergraduates, master's, and doctoral graduates in biomedicine, cosmetics, and chemical engineering graduate each year. Recruitment difficulty is lower than in Guangdong.
Fifth, group strategy. 2024 is the first year of Micropeptide Group's "national layout" strategy. Ningxiang is the first stop in Central China, and two new bases in Southwest (Chengdu) and North China (Tianjin/Hebei) are planned subsequently.
II. What the Ningxiang Factory Actually Completed
From production in July 2024 to now, the Ningxiang factory (Hunan Yi'an Biotechnology Co., Ltd.) has been operating for 2 years. In these 2 years, it has completed several key capabilities that the group lacked in the past:
Completed capability 1: Class II medical device registration certificate industry chain.
Guangdong Micropeptide previously mainly did cosmetics OEM. Although medical device OEM had more than 110 Class II medical device registration filings, the registrant entities were scattered in Guangdong. After Hunan Yi'an was established, the group gradually concentrated the application entities for Class II medical device registration certificates in Hunan Yi'an, so that:
- Registrant entities are concentrated, facilitating cross-product line collaboration;
- Hunan Yi'an, as an independent legal entity, bears independent medical device production and operation responsibilities;
- Policy-wise, it enjoys the convenience of medical device review in Hunan Province (Hunan Provincial Medical Products Administration has a green channel for provincial enterprises).
As of July 2026, Hunan Yi'an already holds 20+ Class II medical device registration certificates, plans to add 30+ throughout 2026, and the ultimate goal is to concentrate 60% of the group's more than 110 Class II medical device registration filings in Hunan Yi'an.
Completed capability 2: Emergency production capacity in Central China.
In the past, shipping from Guangdong to Wuhan took 3-5 days by normal logistics, and 1-2 days by air for urgent orders. After the Ningxiang factory was put into production, the time from order placement to receipt for customers in Wuhan, Changsha, and Nanchang has been shortened to 1-2 days (by road).
Completed capability 3: Central China version of integrated cosmetics + medical devices + disinfectant three certificates.
Guangdong Micropeptide has integrated cosmetics + medical devices + disinfectant three certificates. Hunan Yi'an applied for all three qualifications simultaneously upon establishment, obtained all of them in 2025, and starting in 2026 provides localized integrated three-certificate services for Central China customers.
Completed capability 4: Cross-regional OEM/ODM collaboration under the registrant system.
This is an innovation we made in 2025-2026: Guangdong Micropeptide and Hunan Yi'an have achieved "mutual recognition of registration certificates, mutual connectivity of production capacity, and unified compliance standards." This means:
- Products commissioned by brand owners to Guangdong Micropeptide can simultaneously use Hunan Yi'an's registration certificates;
- Products commissioned by brand owners to Hunan Yi'an can simultaneously use Guangdong Micropeptide's registration certificates;
- The formula standards, raw material suppliers, and quality management systems of the two factories are completely unified.
Value to customers: Brand owners do not need to struggle with "whether to make it in Guangdong or Hunan"; they can flexibly choose based on product positioning, logistics convenience, and emergency response needs. Micropeptide Group automatically coordinates production capacity and registration certificates internally.
III. The "Hard Assets" of the Ningxiang Factory—Doing the Math for Customers
Many customers ask: How is the hardware configuration of the Ningxiang factory? Is there a gap compared with Guangdong?
Let's talk data directly—as of July 2026:
| Dimension | Guangdong Micropeptide | Hunan Yi'an |
| Plant area | 35000m² | 18000m² |
| Cleanroom class | Class 100,000 | Class 100,000 (local Class 10,000) |
| Number of freeze dryers | 13 units (GEA imported) | 4 units (GEA + Tofflon) |
| Filling lines | 12 lines | 6 lines |
| Annual capacity | 50 million units+ | 15 million units+ |
| Testing and inspection equipment | HPLC/GC/IR/UV fully equipped | Equivalent configuration |
| Class II medical device registration filings | 110+ items | Continuously growing |
| Core customer groups | National + South China + East China | Central China + Southwest |
Key difference: The hardware configuration of the Ningxiang factory is at the same level as Guangdong, not a "secondary configuration." Total investment exceeds 350 million, completed in two phases from 2024 to 2026.
IV. Key Actions of the Ningxiang Factory in the Second Half of 2026
Action 1: Add 15 Class II medical device registration certificates. Focus on recombinant collagen series, mussel adhesive protein series, and silk fibroin series. These are the hottest medical device ingredients in the market in 2026.
Action 2: Open "Central China warehouse" service to brand owners. Like the Guangdong warehouse, inventory is interconnected within the group. Emergency orders from Central China customers are shipped directly from the Ningxiang warehouse and arrive in 2-3 days.
Action 3: Make "Made in Hunan" into a brand owner story. Many domestic brands are now talking about "Made in China" and "the light of domestic goods." The Ningxiang factory is a truly tellable "Made in Hunan" story. Brand owners can mention "produced in Ningxiang, Hunan" in product stories, packaging copy, and detail pages.
Action 4: Prepare to build a Central China industry-university-research cooperation base. The Ningxiang factory is negotiating cooperation with Hunan University of Chinese Medicine and Hunan Provincial Institute for Drug Control, and plans to unveil the "Central China Recombinant Collagen Joint Laboratory" in 2027.
V. Three Calculations for Brand Owners
Calculation 1: Logistics cost. For brand owners in Central China finding OEM factories in Guangdong, the logistics cost per unit is about 0.3-0.5 yuan. With Hunan Yi'an, the logistics cost per unit is about 0.1-0.2 yuan. Based on an annual order of 10 million units, saving 2-3 million per year.
Calculation 2: Emergency response. Medical aesthetics channels and chain pharmacy channels have extremely high requirements for replenishment speed. Ningxiang is 1 hour from Changsha, 5 hours from Wuhan, and 4 hours from Nanchang. Emergency orders can be shipped within 24 hours.
Calculation 3: Policy benefits. As a Hunan Province specialized, refined, distinctive and innovative enterprise, Hunan Yi'an's customers' products can apply for the "Made in Hunan" label, which has bonus points in local government procurement, hospital tendering, and medical insurance catalogues.
FAQ | The 5 Most Frequently Asked Questions About Hunan Yi'an
Q1: What exactly is the relationship between Hunan Yi'an and Guangdong Micropeptide?
Mother-son relationship. Guangdong Micropeptide Biotechnology Co., Ltd. is the parent company, and Hunan Yi'an Biotechnology Co., Ltd. is a wholly-owned subsidiary. The group's unified brand "Micropeptide" can be used by both sides. Registration certificates, patents, ISO13485/ISO22716/US GMPC and other qualifications are uniformly held at the group level.
Q2: If I commission Hunan Yi'an for OEM, can I simultaneously use Guangdong Micropeptide's registration certificates?
Yes. Within the group, "registration certificates are mutually recognized." Products produced by brand owners at Hunan Yi'an can simultaneously use Guangdong Micropeptide's registration certificates. The specific operation is stipulated when signing the OEM agreement.
Q3: When will the Ningxiang factory's capacity reach Guangdong's level?
According to the plan, it will reach 25 million units/year by the end of 2027, 35 million units/year by the end of 2028, and 50 million units/year by 2030 (equivalent to Guangdong).
Q4: Does Hunan Yi'an have medical device OEM capability?
Yes. Starting in 2025, Hunan Yi'an began accepting external medical device OEM orders. Customers successfully served include a listed chain medical aesthetics institution, a Central China regional chain pharmacy private label, and an emerging domestic brand.
Q5: If I commission Hunan Yi'an for OEM, is the payment method the same as Guangdong?
The same. 50% prepayment + 50% upon delivery. If customers have special needs (such as payment terms, partial delivery), they can be discussed separately, but group financial approval is required. Micropeptide Group's unified payment policy does not accept oral agreements; all payment terms are written into the OEM agreement.